Latest news
FDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections - Medical DailyMedical Daily · Sat, 08 Aug 2026 14:30:41 GMTReplimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. - Barron'sBarron's · Fri, 07 Aug 2026 19:33:00 GMTFDA Grants Accelerated Approval to Replimune's Tudriqev Plus Nivolumab for Advanced Melanoma - biopharminternational.combiopharminternational.com · Fri, 07 Aug 2026 17:19:39 GMTReplimune's stock jumps after FDA approves its first skin cancer drug Tudriqev - PluangPluang · Fri, 07 Aug 2026 15:51:23 GMTFDA Approves Replimune Skin Cancer Drug After Rejections - MedscapeMedscape · Fri, 07 Aug 2026 13:27:22 GMTTudriqev: US FDA Approves Replimune's Skin Cancer Drug After Rejecting It Twice - Health and MeHealth and Me · Fri, 07 Aug 2026 12:34:03 GMTTwo Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment - BenzingaBenzinga · Fri, 07 Aug 2026 11:49:41 GMTIt’s Official: US FDA Approves Replimune’s Melanoma Drug - The Dermatology DigestThe Dermatology Digest · Thu, 06 Aug 2026 21:37:13 GMT